Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Kimco: Good Yield, Bad "Dividend Quality," I Pass

2018-07-18 seekingalpha
At first glance, 6.6%-yielding Kimco looked like the sort of good-yielding good-quality REIT for which I screened.
BRX

44
Brixmor: A High Yielding (6%-Plus) Good-Quality REIT

2018-07-18 seekingalpha
The old brick-and-mortar world is history. But there’s a lot more to the succession than just Amazon.
JILL SHLD AMZN BRX CLIX SPG.PRJ SPG WMT

2
Can City Office REIT Deliver The Goods?

2018-07-11 seekingalpha
We are maintaining our STRONG BUY recommendation and we believe that as CIO’s dividend becomes safer (payout ratio under 100%) and the valuation gap should tighten.
KIM.PRI STAG.PRB STAG.PRC SKT KRG KIM.PRM KIM.PRL KIM.PRK KIM.PRJ BRX STAG.PRBCL CIO KIM STAG STAG.PRA

235
Vanguard Unleashes The Bull

2018-06-27 seekingalpha
The holdings in the ETF are extremely diverse, with the highest weights going to large REITs with strong fundamentals.
REG DLR.PRH KIM.PRI DLR.PRG DLR.PRJ DLR.PRI DRE AMT.PRB STAG.PRB AMT.PRA STAG.PRC TCO KIM.PRM KIM.PRL KIM.PRK KIM.PRJ AMZN AMT ESS CCI.PRA CCI GGP MAC KIM STAG STAG.PRA REG.PRG REG.PRF EQIX TCO.PRK TCO.PRJ DRE.PRO PLD BRX SPG.PRJ T VZ STAG.PRBCL DLR SPG SBAC DLR.PRC WPG DLR.PRF DRE.PRL CBL

11
Kimco And Brixmor: Which Is A Better Buy?

2018-06-20 seekingalpha
BRX has a longer growth runway, a cheaper valuation, and a higher dividend plus buyback yield.
KIM.PRI BRX KIM.PRM KIM KIM.PRL KIM.PRK KIM.PRJ

13
Short seller targets Healthcare Trust of America over earnings concerns - MarketWatch

2018-06-10 marketwatch
Healthcare Trust of America, Inc. HTA, -1.19% is a real estate investment trust with a track record of consistent returns in a growth industry with demographics working in its favor. The stock has an “overweight” rating by analysts, according to the FactSet-compiled consensus. And in May, it got a little plug from MarketWatch when an analyst we interviewed noted it on his “buy” list.
BRX HTA

11
BRX / Brixmor Property Group Inc. / JP Morgan Chase & Co - NONE (Passive Investment)

2018-06-07 sec.gov
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BRX

13
BRX / Brixmor Property Group Inc. / JP Morgan Chase & Co - NONE (Passive Investment)

2018-06-07 sec.gov
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BRX

221
Retiring With Higher Yields

2018-06-07 seekingalpha
Whether you recently entered retirement or are planning to do so, you may be hunting for solid dividend stocks.
COR.PRACL O.PRF OPRF TCO CIM COR EQR ESS AAPL GGP MO MAA CIM.PRA EQIX TCO.PRK TCO.PRJ O CIM.PRB GGP.PRA COR.PRA NNN.PRD NNN.PRF NNN.PRE BRX SPG.PRJ CPT JNJ SPG NNN

91
5 Good, Bad And Ugly Dividend Stocks At Current Market Prices

2018-06-03 seekingalpha
Here, at “The REIT Forum”, we try to find good investments at great valuations. We also spot bad investments and attempt to steer investors away from them.
WFCNP WFC.PRL BATS WFC.PRJ 4162 TCO WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY GGP WFC.PRX WFC.PRW WFC.PRV MO WFC WFC.WS TCO.PRK TCO.PRJ GGP.PRA BRX SPG.PRJ MSFT SPG

74
Top Analyst Upgrades and Downgrades: Aimmune, Anadarko, Carrizo, Mastercard, PayPal, Spotify, Visa and More

2018-05-18 247wallst
Stocks were indicated marginally higher on Friday, but the direction of the day seems far from set in stone. The trend of endlessly buying the dips has not worked as well as it has in prior years. Now is a time when all investors should be considering how they want their investments positioned for the longer term.
SBS CRZO V BRX BERY AIMT MA TRI ADVM ALPN COUP

18
How To Retire Today With $1 Million

2018-05-18 seekingalpha
As the author of The REIT Forum, we focus on high yields with relatively low risk. Preferred shares are a safe way to raise your income compared to the common stock. I recently wrote a guide for preferred shares for investors.
BRX SPG.PRJ EQR SKT SPG GPMT

50
30 Top Dividend Challenger Gains Led By EQT Midstream Partners, Hoegh LNG Partners, And Westlake Chemical Per Broker Targets For May

2018-05-09 seekingalpha
30 Top Dividend Challenger stocks ranged in yield from 7.13% to 12.32%. The top 10 were PBVX, SIR, DDR, HMLP, ABR, DKL, NRZ, SRLP, GME, and SUN.
HMLP KRG DDR.PRJ ABRN EQM PBFX DDR.PRK DKL SUN DDR.PRA BGS ABR DDR PEGI NRZ WLK GME SRLP BRX ABRN.CL SIR PEG ABR.PRB HMLP.PRA ABR.PRC ABR.PRA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BRX / Brixmor Property Group Inc. on message board site Silicon Investor.

MBRX under $3 announced big break through for Leukemia Metabasis Therapeutics (MBRX)
SBRX - Stonebridge Resources Explorations Ltd. ABRX ABLE LABS
ABRX: ABR Information Services ABR Information Services (ABRX)
CUSIP: 11120U105